RU2012119488A - Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором - Google Patents

Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором Download PDF

Info

Publication number
RU2012119488A
RU2012119488A RU2012119488/04A RU2012119488A RU2012119488A RU 2012119488 A RU2012119488 A RU 2012119488A RU 2012119488/04 A RU2012119488/04 A RU 2012119488/04A RU 2012119488 A RU2012119488 A RU 2012119488A RU 2012119488 A RU2012119488 A RU 2012119488A
Authority
RU
Russia
Prior art keywords
alkyl
cycloalkyl
heterocyclic derivative
optionally substituted
group
Prior art date
Application number
RU2012119488/04A
Other languages
English (en)
Russian (ru)
Inventor
Пол Дэвид РЭТКЛИФФ
Томас Расселл КЛАРКСОН
Фиона ДЖЕРЕМАЯ
Джон Киннэйрд Фергусон МАКЛИН
Original Assignee
Мсд Осс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мсд Осс Б.В. filed Critical Мсд Осс Б.В.
Publication of RU2012119488A publication Critical patent/RU2012119488A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2012119488/04A 2009-10-13 2010-10-11 Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором RU2012119488A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25110109P 2009-10-13 2009-10-13
EP09172872 2009-10-13
EP09172872.5 2009-10-13
US61/251,101 2009-10-13
PCT/EP2010/065160 WO2011045258A1 (en) 2009-10-13 2010-10-11 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor

Publications (1)

Publication Number Publication Date
RU2012119488A true RU2012119488A (ru) 2013-11-20

Family

ID=42040651

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012119488/04A RU2012119488A (ru) 2009-10-13 2010-10-11 Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором

Country Status (12)

Country Link
US (1) US8841289B2 (enExample)
EP (1) EP2488520B1 (enExample)
JP (1) JP2013507417A (enExample)
KR (1) KR20120100913A (enExample)
CN (1) CN102666540A (enExample)
AU (1) AU2010305825A1 (enExample)
BR (1) BR112012008518A2 (enExample)
CA (1) CA2776835A1 (enExample)
IN (1) IN2012DN02968A (enExample)
MX (1) MX2012004289A (enExample)
RU (1) RU2012119488A (enExample)
WO (1) WO2011045258A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2563232T3 (es) 2011-07-29 2016-03-11 Taisho Pharmaceutical Co., Ltd. Compuesto de amidina o sal del mismo
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US20150164858A1 (en) * 2012-05-22 2015-06-18 King Abdullah University Of Science And Technology Combination comprising parthenolide for use in the treatment of alzheimer's disease and other neurodegenerative disorders
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
EP3191459A1 (en) 2014-09-05 2017-07-19 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
EP3623371A1 (en) 2014-12-16 2020-03-18 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶
HK1248222A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 噻吩并嘧啶酮作为泛素特异性蛋白酶7抑制剂
HK1248221A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 异噻唑啉酮类,吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂
HK1248220A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂
CN106146410B (zh) * 2015-04-03 2018-10-12 中南大学 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
CN106279211B (zh) * 2015-06-03 2020-09-15 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
CA2988968A1 (en) 2015-06-10 2016-12-15 Forum Pharmaceuticals, Inc. Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
WO2017027600A1 (en) 2015-08-12 2017-02-16 Forum Pharmaceuticals, Inc. GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS
US10500205B2 (en) 2015-12-09 2019-12-10 Cadent Therapeutics, Inc. Thienopyrimidinone NMDA receptor modulators and uses thereof
ES2821010T3 (es) 2015-12-09 2021-04-23 Cadent Therapeutics Inc Moduladores heteroaromáticos del receptor NMDA y usos de los mismos
CA3047403A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics, Inc. Nmda receptor modulators and uses thereof
CA3105174A1 (en) * 2018-06-27 2020-01-02 Reborna Biosciences, Inc. Prophylactic or therapeutic agent for spinal muscular atrophy
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
CA3102326A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
CA3108519A1 (en) 2018-08-03 2020-04-30 Cadent Therapeutics, Inc. Heteroaromatic nmda receptor modulators and uses thereof
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
WO2021198188A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
EP4204418A1 (en) 2020-08-28 2023-07-05 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
CN112898290B (zh) * 2021-01-29 2022-08-05 中南大学 异噁唑甲酰胺基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
TW202539670A (zh) * 2024-02-23 2025-10-16 大陸商海思科醫藥集團股份有限公司 Braf抑制劑的製備方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
JP2005504730A (ja) * 2001-04-20 2005-02-17 バーテックス ファーマシューティカルズ インコーポレイテッド Gsk−3インヒビターとして有用な組成物
WO2003062235A1 (en) 2002-01-17 2003-07-31 Eli Lilly And Company Modulators of acetylcholine receptors
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
TW200536830A (en) * 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
PT1910333E (pt) * 2005-07-26 2013-08-01 Sanofi Sa Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
CN101600698B (zh) 2006-09-11 2012-01-11 欧加农股份有限公司;药典有限责任公司 喹唑啉酮和异喹啉酮乙酰胺衍生物
JP5313919B2 (ja) * 2006-12-27 2013-10-09 サノフイ 新規な置換イソキノリン及びイソキノリノン誘導体
JP2010229035A (ja) * 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd ピリドピリミジン−4−オン誘導体
BRPI0820259A2 (pt) * 2007-11-14 2015-06-16 Neurosearch As Derivado de 1,4-diaza-biciclo[3.2.2] nonil pirimidina, composição farmacêutica, uso do derivado de 1,4-diaza-biciclo[3.2.2] nonil pirimidina, e, método de tratamento, prevenção ou alívio de uma doença ou uma desordem ou uma condição de um corpo de animal vivo
WO2009107236A1 (ja) 2008-02-29 2009-09-03 テクノコアインターナショナル株式会社 パック電池の充電装置及びパック電池の品質判定装置

Also Published As

Publication number Publication date
EP2488520A1 (en) 2012-08-22
WO2011045258A1 (en) 2011-04-21
AU2010305825A1 (en) 2012-04-19
JP2013507417A (ja) 2013-03-04
CN102666540A (zh) 2012-09-12
US8841289B2 (en) 2014-09-23
BR112012008518A2 (pt) 2016-04-05
MX2012004289A (es) 2012-06-12
CA2776835A1 (en) 2011-04-21
US20120208796A1 (en) 2012-08-16
EP2488520B1 (en) 2015-09-02
KR20120100913A (ko) 2012-09-12
IN2012DN02968A (enExample) 2015-07-31

Similar Documents

Publication Publication Date Title
KR102594476B1 (ko) C-kit 억제제로서의 아미노티아졸 화합물
AU2010297921B2 (en) Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof
ES2928169T3 (es) Derivados de 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amina como inhibidores de proteína cinasa, y método de preparación y uso médico de los mismos
CN112442050A (zh) 一种ret抑制剂、其药物组合物及其用途
BR112019012957A2 (pt) derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1
BR102014017997B1 (pt) compostos do tipo fosfato, processo para sua preparação, composições farmacêuticas contendo os mesmos, seus usos e associações
CN104725359B (zh) 取代的哌嗪化合物及其使用方法和用途
WO2019165073A1 (en) Shp2 phosphatase inhibitors and methods of use thereof
AU2014221799A1 (en) Novel pyrazole derivative
RU2012148246A (ru) 5, 7- замещенные-имидазо[1, 2-с]пиримидины как ингибиторы jak-киназ
ES3062921T3 (en) Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method
JP2009507032A (ja) 新規なイミダゾ系複素環
WO2019241292A1 (en) Hepatitis b capsid assembly modulators
AR049300A1 (es) Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
JP2016523270A5 (enExample)
RU2008125040A (ru) ПРОИЗВОДНЫЕ АРИЛ-ИЗОКСАЗОЛ-4-ИЛ-ИМИДАЗО[1.5-a]ПИРИДИНА
JP2023537055A (ja) Atr阻害剤およびその使用
JP2018522909A (ja) ヒト免疫不全ウイルス複製の阻害剤としての5−(n−縮合三環式アリールテトラヒドロイソキノリン−6−イル)ピリジン−3−イル酢酸誘導体
AU2017265383B2 (en) Treatment of neurological disorders
RU2015102095A (ru) 3-о-гетероарилингенол
AU2015316719A1 (en) Imidazo[2,1-b]thiazole and 5,6-dihydroimidazo[2,1-b]thiazole derivatives useful as S100-inhibitors
AR052019A1 (es) COMPUESTOS HETEROCICLICOS, PROCESOS DE PREPARACIoN Y MÉTODO PARA TRATAR ENFERMEDADES HIPERPROLIFERATIVAS
EA201792087A1 (ru) ПРОИЗВОДНЫЕ 7-(МОРФОЛИН-4-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИМИДИНА, ПРИГОДНЫЕ ДЛЯ ЛЕЧЕНИЯ ИММУННЫХ ИЛИ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ИЛИ РАКА
JP2018522913A (ja) ヒト免疫不全ウイルス複製の阻害剤としての5−(n−[6,5]−縮合二環式アリールテトラヒドロイソキノリン−6−イル)ピリジン−3−イル酢酸誘導体
ES2628818T3 (es) Compuestos triazólicos tricíclicos como ligandos de receptores sigma